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Summary
Introduction: As osteoclast, giant cell tumors express calcitonin receptors. The aim of this
paper is to assess treatment using salmon calcitonin after curettage.
Material and methods: We retrospectively reviewed 25 patients with giant cell tumor of the
appendicular skeleton treated with a single protocol of calcitonin administration following
curettage in order to assess the effectiveness of calcitonin in reducing the rate of local recur-
rence.
Results: The mean duration follow-up was 68 months. Thirteen patients (52%) had local recur-
rence. Eight of them were treated successfully after repeated curettage and calcitonin. Four
patients had bone resection and one patient had curettage and cement ﬁlling. All patients
with cavity left empty had ossiﬁed and the functional score as assessed by the MSTS score was
28.02/30.
Conclusion: This study suggests that the use of calcitonin as adjuvant is not effective and that
ﬁlling agents are not required after curettage of giant cell tumors.
Level of evidence: Level 4.
© 2011 Published by Elsevier Masson SAS.
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iant cell tumors (GCTs) represent approximately 15—20%
f nonmalignant bone lesions and are described as stage
or 3 lesions, benign but locally aggressive, with a typi-al recurrence rate after curettage alone approaching 50%
1—4]. Over the years, many different adjuvant therapies
ave been suggested, ranging from mechanical, chemical, to
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oi:10.1016/j.otsr.2011.03.019hermal, biologic, injection, and embolization treatments.
he purpose of these modalities is the control of microscopic
isease in the reactive zone after curettage has removed the
ross tumor.
It has been demonstrated that giant cells express calci-
onin receptors. Nicholson et al. [5] and Flanagan et al. [6],
n an immunohistochemical study using osteoclast-speciﬁc
onoclonal antibodies, were the ﬁrst to demonstrate that
iant cells in chronic giant cell granulomas (CGCGs) are
steoclasts. Therefore, giant cells are directly inhibited in
heir function by calcitonin, which causes an increasing
nﬂux of calcium into the bones and, thus, functions antag-
nistically to parathormone.
.
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Table 1 Descriptive characteristics.
Age
31.8± 12.7 (13—70)
Sex
M/F: 5/20
Location: nb (%)
PT: 10 (40)
DF: 7 (28)
DR: 3 (12)
PH: 2 (8)
PU: 1 (4)
PF: 1 (4)
DT: 1 (4)
Campanacci grade
GI: 4 (16%)
GII: 18 (72)
GIII: 3 (12)
Tumor size
< 50%: 7 (28%)
> 50%: 15 (60)
> 100%: 3 (12)
Pathological fracture
7 (28%)
Local recurrence
13 (52%)
Time to recurrence (month)
40.5± 41.6 (range: 2—180)
M: male; F: female; PT: proximal tibia; DF: distal femur; DR:
distal radius; PH: proximal humerus; PU; proximal ulna; PF:
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The aim of this paper is to report the results of the
treatment of GCT of bone with a single protocol of salmon
calcitonin after curettage.
Material and method
We retrospectively reviewed the charts of 25 patients with a
GCT of the appendicular skeleton treated at our institution
between 1990 and 2007 by a single protocol of curettage and
calcitonin. Clinical, radiological and histological data were
reviewed and the outcome was assessed with a minimum
follow up of 3 years.
The GCTs were graded radiologically according to the sys-
tem described by Campanacci et al. [7]. The percentage of
the epiphysis occupied by the tumor was calculated bas-
ing on plane radiographs and CT scan. Histological diagnosis
was conﬁrmed by biopsy before any therapeutic procedure.
All the cases were benign GCTs. The therapeutic protocol is
composed of four successive steps which were applied for
all patients:
• First step is curettage: a cortical fenestration was made
with an osteotome. The tumor was removed with curettes
of different sizes. Then the cavity was irrigated with ster-
ile saline, injected with 100 to 200 IU of calcitonin and was
not ﬁlled in.
• Second step: postoperatively, patients received intramus-
cular injection of 100 IU of calcitonin each day for 15
days.
• Third step: after healing of the operative scar, we per-
formed intralesional injection of 100 IU of calcitonin each
day for one month.
• Fourth step: for 2 months, patients received intra muscu-
lar injection of 100 IU of calcitonin each day.
Patients with a lesion on the lower limb used no weight
for not more than 3 months after the operation. Patients
were followed once a month until the reossiﬁcation of the
cavity was conﬁrmed, then each 3months the ﬁrst year then
twice a year for 5 years. At each check up, clinical exami-
nation, plain radiograph of the involved bone and the chest
were obtained. MRI or CT examinations were made at 6- or
12-month intervals to evaluate bone formation and detect
local recurrence for 2 years. No CT scan of the lung was
performed.
Local recurrence was suspected radiologically then con-
ﬁrmed histologically. The mean follow up was 67.8± 30.57
months (median: 60, range 36 to 180). The Musculo Skeletal
Tumor Society score developed by Enneking et al. [8] was
used to assess the functional score.
Statistical Analysis was carried out using the Statisti-
cal Package for the Social Sciences (SPSS) software version
17.0 (SPSS Inc., Chicago, USA). Yates’ corrected x2-test and
Kaplan-Meier survival analysis by log-rank test were per-
formed. A p value < 0.05 was considered signiﬁcant.
ResultsThere were ﬁve males and 20 females (sex ratio: 1/4). The
mean age was 31.8± 12.7 years (range 13 to 73). The most
common site was about the knee with 40% occurring in the
c
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1proximal femur; DT: distal tinia.
roximal tibia and 28% in the distal femur (Table 1). The
ampanacci grades were I in 4 cases, II in 18 cases and III in
cases. Seven patients had pathological fracture at presen-
ation (case 1). Three of them were managed nonoperatively
nd 4 were stabilised by external ﬁxation.
On plan radiographs the lesions began to show bone for-
ation at 1 month after curettage (case 2). On CT scan, we
bserved that the cavity tended to heal by thickening of the
ortex and then by development of septae running across the
efect that gradually became radiopaque, although com-
lete bone ﬁlling of all cavities was not achieved (case3). In
ne case, we performed a biopsy at the radiolucent areas
Fig. 1C). Histological examination revealed a ﬁbrous tissue.
he cortical defect performed for exposure was visible for a
ong time but with no mechanical consequences (Fig. 2dE).
t the last follow up, all the patients with a cavity left empty
20 patients) healed. The average time to bone healing, as
udged by allowing weight bearing, was 10 weeks (range 6
o 12). Although there was a trend for larger cysts (over 50%
f the epiphysis) to take slightly longer to heal, this was
ot statistically signiﬁcant. Five patients had degenerative
hanges on articular cartilage (Fig. 3C).The overall rate of local recurrence was 52% (13
atients). Local recurrences occurred by a mean time of
0.7± 15.9 months (median 5 months). Sixty one percent of
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Figure 1 Case 1. A: A 28-year-old woman with grade II GCT of the distal femur revealed by a pathological fracture. The lesion was
treated with curettage and Calcitonin. The fracture was managed nonoperatively by a plaster. B: At 6months, we note an excellent
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seossiﬁcation of the lesion. C: CT scan of the knee showing the
ﬁbrous tissue but not a residual tumor which was conﬁrmed in
hem occurred within the ﬁrst 6 months. The longest local
ecurrence occurred after 5 years (Fig. 4).
The local recurrence rate varied signiﬁcantly with Cam-
anacci grade, being 25% in grade I, 50% in grade II and 100%
n grade III (p = 0.005). Neither the size of the tumor nor
athologic fracture did correlate with local recurrence.
The ﬁrst local recurrence was treated by the same pro-
ocol in 11 patients. One patient had wide resection of the
bula head and one patient was treated by curettage and
ement ﬁlling for a tumor of the proximal tibia.
The success rate of the second protocol was 7 to 11
63.6%). The patients with additional local recurrences were
reated by wide resection and arthrodesis in three cases and
ne patient healed after repeated curettage and calcitonin.
Therefore, 20 patients (80%) were treated successfully by
ur protocol: twelve after one course of treatment, 7 after
courses and one after four courses.
None of the patients developed a postoperative infection
nd none of them was reoperated for a mechanical failure
nless a local recurrence occurred.
The Enneking functional score was documented in these
0 patients with a mean score of 28.02/30 (93.4%).
iscussion
he therapeutic concept for administration of calcitonin in
he treatment of GCT is based on an immunohistochemical
tudy that demonstrated that giant cells in GCT are osteo-
lasts [6]. This was suspected from the in vitro reaction of
iant cells to calcitonin and the behaviour of giant cells in
ortical bone causing bone excavation similarly to osteo-
lasts [6,9]. Later on, it was demonstrated that giant cells
re directly inhibited in their function by calcitonin [10].
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gsiﬁcation of the lesion. The nonreossiﬁed areas are ﬁlled with
case by a biopsy.
In 1993, Harris [11] was the ﬁrst to report the use of
uman calcitonin as a therapy for central giant cell granu-
oma (CGCG) of the mandible. The successful use of human
alcitonin in the treatment of CGCG of the jaw has also
een demonstrated by others [12—14]. At present, only
almon calcitonin is commercially available. Theoretically,
he effect of salmon calcitonin is stronger than the effect
f human synthetic calcitonin: 50 IU of salmon calcitonin
ppears to be equipotent with 75 to 90 IU of HC [15]. An in
itro study showed that there is no difference in the effect of
uman or salmon calcitonin on the inhibition of osteoclastic
one resorption [16].
The effectiveness of calcitonin on GCT remains unclear.
nly one double-blind placebo-controlled clinical trial to
valuate the effect of salmon calcitonin was published
17]. The results of this study showed a variable response
f the patients to the calcitonin therapy. During the
-month placebo-controlled period and at the end of treat-
ent/follow up, no signiﬁcant differences in tumor size
eduction were observed between the groups. Overall, con-
iderable reductions in tumor size were seen in half of the
atients at 6months follow-up. However, complete remis-
ions were not observed. Because of the limited number of
atients enrolled in this study and the relatively small effect
f calcitonin, the power of the study is restricted.
To our knowledge, this is the ﬁrst report of the use of
alcitonin as adjuvant after curettage of GCT of skeletal
ones. Our rate of local recurrence of 52% is one of the
ighest reported in literature and concurred with that of old
eries using curettage alone without adjuvants [18,7,19,20].
n recent series, this rate ranges from 0 to 20% [21—26]
Table 2). Many authors advocate the role of adjuvants in
educing the rate of local recurrence. In 2008, a collective
roup studied local recurrence after intralesional treatment
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Figure 2 Case 2. A: A 32-year-old woman with a GCT of the proximal tibia. B: plan radiographs one month after curettage and
calcitonine protocol. C: after 2 months, we note a progressive reossiﬁcation of the lesion. D: The lesion healed after 3 months.
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reossiﬁcation of the lesion without local recurrence neither car
with and without adjuvants, covering several adjuvants, in
both primary and recurrent lesions in 384 procedures [20].
The results showed a rate of recurrence of 50% without adju-
vants, and a range of 15—27% with adjuvants. Another study
of 214 patients concluded that adjuvant therapy (with bur-
ring, hydrogen peroxide and cementation) is recommended
over curettage alone; 12% compared with 65% recurrence
[27].
However, evidences provided concerning the real effect
of these different adjuvants are debated, since the major-
ity of large series involved heterogeneous groups of patients
treated by different modalities over long periods of time.
And there were never any prospective randomized stud-
ies published. Turcott et al. [23] reported a series of 148
patients who had curettage and could not identify any signif-
icant statistical effect on local recurrence by any adjuvant
therapy including phenol, nitrogen and cement. In a recent
study, Errani et al. [21] reviewed the experience of the Riz-
zoli institute. Two hundred patients underwent curettage of
the lesion and in 64 of these cases, three local adjuvants,
such as phenol, alcohol and cement, were employed. The
t
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tl window resected for exposure. E: at 2 years, we note a good
inous change.
ocal recurrence was 12.5% in patients treated by intrale-
ional surgery and three local adjuvants. Conversely, it was
igher in the second group of patients with an incidence of
8% of cases. However, the authors were unable to prove the
utative value of single adjuvants.
With increasing understanding of the biology of GCT come
ovel and unique treatment options. The stromal cells in
CT produce RANK ligand, the factor that stimulates the
ctivation of the osteoclast, causing bone resorption [28] It
s this mechanism, also seen in metastatic disease and osteo-
orosis, that is targeted by the bisphosphonates. In a recent
etrospective case-control study by Tse et al. [29] patients
ith GCT were treated with curettage, burring and cemen-
ation, with one group receiving bisphosphonates. There
ere 20 control patients compared to the 24 trial patients
ho received both preoperative and postoperative intra-
enous bisphosphonates, with 3 months of oral treatment
hereafter. There was a 4.2% recurrence rate compared with
0% in the control group. The antagonist to RANK ligand in
steoclast activation is osteoprotegrin (OPG), and the selec-
ive estrogen receptor modulator reloxifene has been shown
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Figure 3 Case 3. A: A 47-year-old woman with grade II GCT of the proximal tibia, treated with curettage and Calcitonin. B: there
was a local recurrence and progression of the lesion to grade III at 3months, treated with a second course. C: At 7 years, there was
no local recurrence, remodelling of the cavity was excellent and the patient developed osteoarthritis. D: CT scan of the recurrence
showing the destruction of the epiphysis and the extra osseous extension of the tumor. E: at the end of the second course, thickening
of the cortex. F: at the last follow-up, excellent bone formation.
Table 2 Reported rates of recurrence after primary curettage.
Authors Year Number Additional treatments Recurrence (%)
Campanacci [19] 1987 106 None 34
16 Phenol 13
6 Nitrogen 0
2 Cement 0
Capanna et al. [20] 1990 280 None 45
187 Cement 19
147 Phenol 19
20 Nitrogen 19
33 Cement + phenol 3
Masui et al. [18] 1998 17 None 47
Blackley et al. [27] 1999 59 Bone graft 12
Gherl et al. [26] 2002 47 Cement + phenol or electrocautery 13
Ward and Li [25] 2002 24 H2O2, phenol, electrocautery, cement 8
Turcotte et al. [24] 2002 120 None, cement, phenol, liquid nitrogen 12
Prosser et al. [23] 2005 137 None 19
Errani et al. [22] 2010 200 Phenol, alcohol, cement, bone graft 12
Present series 2010 25 Calcitonin 52
Calcitonin use in giant cell bone tumors
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to promote OPG. It has been suggested that this too can
be an adjuvant for osteoclast mediated bone lysis in benign
bone tumors [30]. However, these encouraging results need
to be assessed by further controlled studies.
We think that our high rate of local recurrence is related
to a lack of accuracy of the primary curettage since 60%
of the local recurrences occurred during the ﬁrst 6months
(Fig. 4). One factor that points in that direction would be
the observation that the rate of ﬁrst recurrences of primary
tumors was higher than the rate of second recurrences of
tumors treated with the same protocol (52% vs 36%: sta-
tistically not signiﬁcant). Moreover, we observed in two
recurrent cases a progression of the tumor to a grade III. Sur-
prisingly, both healed after the second therapeutic course
(case 3) because of a more aggressive curettage.
Several authors have dealt with the topic of thorough-
ness. Becker et al. [20] reported better results, after
curettage without adjuvants, for the recurrent tumors and
the Campanacci grade-III tumors as compared with their less
at-risk appearing counterparts. He concluded that the curet-
tage used for the tumors that had appeared to be at higher
risk was of higher quality or accuracy. In a review of 137
patients with GCTs of skeletal bone treated by curettage
alone without any adjuvant, Prosser et al. [22] reported an
overall rate of local recurrence of 19%. Even in recurrent
cases, repeated curettage without adjuvant was effective.
One hundred and twenty-ﬁve patients (91%) were treated
successfully by this procedure. They concluded that detailed
and extensive curettage without adjuvant therapy or ﬁll-
ing agents is effective in grade I and II lesions. Capanna
et al. [19] observed a recurrence rate of 26% following expo-
sures that were wide (more than one half of the tumor
length) as compared with 48% following exposures with a
smaller window. Other authors have recommended the use
of a burr [21,22,24] in order to increase the thoroughness
of the curettage. Blackley et al. [1] reported a recurrence
rate of 12% after this procedure. According to Rock et al.
[31], the thoroughness of the curettage was improved by the525
ider exposure necessary for phenolization. Trieb et al. [32]
eported no beneﬁt of using phenol and advocated thorough
emoval of the tumor. More recently in 2010, Algawahamed
t al. [33] reviewed systematically the literature and have
etained six studies evaluating adult patients diagnosed with
rimary or recurrent GCT of bone treated with curettage and
igh speed burr with or without a local adjuvant. Adjuvant
odalities were phenol, bone cement and liquid nitrogen.
hey demonstrated that adjuvants are not necessary to
educe recurrence rates and concluded that meticulous sur-
ical technique including high speed burring is the most
mportant step in reducing recurrence rates in GCT of bones.
The reasons for ﬁlling the defect after curettage of a GCT
re to increase ﬁnal bone strength and to reduce the risk of
ocal recurrence. Like others [22,34,35], we think that this
s not necessary since spontaneous reossiﬁcation of the cav-
ty is possible. Some experimental data showed that bone
efects that are left empty, heal just as well as when ﬁlled
ith a bone substitution [36,37]. Clinical studies including
urs demonstrated the natural ability of the cavity to ﬁll
fter curettage as the sole treatment in benign bony lesions
22,34,35]. Moreover keeping the cavity empty avoids dis-
dvantages of ﬁlling material such as mechanical problems,
ost, infection and availability. Hirn et al. [34] think that
part from bone cement, most substances that are used to
ll defects have no inherent strength and rely upon bone in
rowth for strength. Thus these patients will be as much at
he same risk of fracture or collapse of the joint surface as
hose without any ﬁlling until the bone has consolidated.
onclusion
he current study is a retrospective review of patients from
ne institution. Although it is limited by the single protocol
ith no attempt to randomize cases, the effect of calcitonin
n preventing local recurrence seems to be very limited.
herefore, we suggest that ﬁlling agents are not required
fter curettage of GCT.
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